期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

甲状腺癌的分子生物学研究进展 被引量：3

Progress of molecular biology in thyroid carcinoma
原文传递
导出
摘要 甲状腺癌是内分泌系统最常见的恶性肿瘤，多发于女性患者。不同病理类型的甲状腺癌，其生物学行为不同，且发病比较隐匿，故目前对甲状腺癌的早期诊断仍比较困难。近年来随着分子生物学的发展，对甲状腺癌的肿瘤标志物、癌基因及分子治疗研究较多。本文将对这三个方面的研究进展作一综述。 Thyroid carcinoma is the most frequent endocrine cancer, and most are found in women. Different pathologic types of thyroid carcinoma has different biologic behaviors, and onset is hidden, which re, suits in difficuhs to diagnose the early thyroid carcinoma. With the development of the molecular biology, more researches are focus on thyroid carcinoma in recent years. This article reviews the tumor markers, oncogene and gene therapy of thyroid carcinoma.
作者 王云龙 巩鹏
机构地区 南阳医专第一附属医院普通外科 大连医科大学附属第一医院普通外科
出处 《国际外科学杂志》 2011年第2期109-112,共4页 International Journal of Surgery
关键词 甲状腺癌 肿瘤标志物 分子生物学 癌基因 基因治疗 Thyroid neoplasms Tumor markers Molecular biology Oncogenes Gene therapy
分类号 R736.1 [医药卫生—肿瘤]
  • 相关文献

参考文献26

  • 1Boldarine VT,Maciel RM,Guimar(a)es GS,et al.Development of a sensitive and specific quantitative reverse transcription-polymerase chain reaction assay for blood thyroglobulin messenger ribonucleic acid in the follow-up of patients with differentiated thyroid carcinoma[J].J Clin Endocrinol Metab,2010,95 (4):1726-1733.
  • 2Jeon S J,Kim E,Park JS,et al.Diagnostic benefit of thyroglobulin measurement in fine-needle aspiration for diagnosing metastatic cervical lymph nodes from papillary thyroid cancer:correlations with US features[J].Korean J Radiol,2009,10(2):106-111.
  • 3Hsiao PJ,Lu MY,Chiang FY,et al.Vascular endothelial growth factor gene polymorphisms in thyroid cancer[J].J Endocrinol,2007,195(2):265-270.
  • 4de Araujo-Filho VJ,Alves VA,de Castro IV,et al.Vascular endothelial growth factor expression in invasive papillary thyroid carcinoma[J].Thyroid,2009,19(11):1233-1237.
  • 5De la Torre NG,Buley I,Wass JA,et al.Angiogenesis and lymphangiogenesis in thyroid proliferative lesions:relationship to type and tumour behaviour[J].Endocr Relat Cancer,2006,13(3):931-944.
  • 6彭年春,郭晓蕙,袁振芳,高燕明.CD26及半乳糖凝集素3免疫组织化学染色在甲状腺癌诊断中的应用[J].中华内分泌代谢杂志,2006,22(2):178-182. 被引量：12
  • 7Weinberger PM,Adam BL,Gourin CG,et al.Association of nuclear,cytoplasmic expression of galectin-3 with beta-catenin/Wntpathway activation in thyroid carcinoma[J].Arch Otolaryngol Head Neck Surg,2007,133(5):503-510.
  • 8Murphy KM,Chen F,Clark DP.Identification of immunohistochemical biomarkers for papillary thyroid carcinoma using gene expression profiling[J].Hum Pathol,2008,39 (3):420-426.
  • 9Aron M,Kapila K,Verma K.Utility of galectin 3 expression in thyroid aspirates as a diagnostic marker in differentiating benign from malignant thyroid neoplasms[J].Indian J Pathol Microbiol,2006,49(3):376-380.
  • 10Londero SC,Godballe C,Krogdahl A,et al.Papillary microcarcinoma of the thyroid gland:Is the immunohistochemical expression of cyclin D1 or galectin-3 in primary tumour an indicator of metastatic disease[J].Acta Oncol,2008,47 (3):451-457.

二级参考文献29

  • 1许良中,杨文涛.免疫组织化学反应结果的判断标准[J].中国癌症杂志,1996,6(4):229-231. 被引量：1360
  • 2郑璐滢,朱建善,王家东,许雁萍.Galectin-3、CK19和TPO表达在甲状腺良恶性肿瘤病理诊断中的价值[J].临床与实验病理学杂志,2005,21(4):449-453. 被引量：18
  • 3Sahoo S, Hoda SA, Rosai J, et al. Cytokeratin 19 immunoreactivity in the diagnosis of papillary thyroid carcino ma: a note of caution [J] . Am J Clin Pathol, 2001, 116 (5): 696-702.
  • 4de Matos PS, Ferreira AP, de Oliveira, et al. Usefulness of HBME, cytokeratin 19 and galectin-3 immunostaining in the diagnosis of thyroid malignancy [ J ] . Histopathology, 2005, 47 (4) : 391-401.
  • 5Seiberling KA, Dutra J, Grant T, et al. Role of intrathyroidal calcifications detected on ultrasound as a marker of malignancy [ J] . Laryngoscope, 2004, 114 (10) : 1753-1757.
  • 6Mackenzie EJ, Mortimer RH. Thyroid nodules and thyroid cancer [J] . Med J Aust, 2004, 180 (5): 242- 247.
  • 7Nix P, Nicolaides A, Coatesworth AP. Thyroid cancer review 1: presentation and investigation of thyroid cancer [J] . Int J Clin Pract, 2005, 59 (11) : 1340-1344.
  • 8Finley D J, Zhu B, Barden CB, et al. Discrimination of benign and malignant thyroid nodules by molecular profiling [J] . Ann Surg, 2004, 240 (3): 425-437.
  • 9Eldar S, Sabo E, Cohen A, et al. The value of histomorphometric nuclear parameters in the diagnosis of well differentiated follicular carcinomas and follicular adenomas of the thyroid gland [ J] . Histopathology, 1999, 34 (5) : 453-461.
  • 10Shin E, Chung WY, Yang WI, et al. RET/PTC and CK19 expression in papillary thyroid carcinoma and its clinicopathologic correlation [ J ] . J Korean Med Sci, 2005, 20 (1): 98-104.

共引文献18

同被引文献50

  • 1Xiang J, Wu Y, Li DS, et al. New clinical features of thyroid cancer in eastern China [J]. J ViscSurg, 2010, 147(5 Suppl): 53-56.
  • 2Adeniran AJ, Zhu Z, Gandhi M, et al. Correlation between ge netic alterations and microscopic features, clinical manifesta tions, and prognostic characteristics of thyroid papillary carcino mas [J]. Am J Surg Pathol, 2006, a0(2) :216-222.
  • 3Knauf JA, Sartor MA, Medvedovic M, et al. Progression of BRAF-induced thyroid cancer is associated with epithelial-mes- enchymal transition requiring concomitant MAP kinase and TGFβ signaling[J].Oncogene, 2011, 30(28):3153-3162.
  • 4Santarpia L, Myers JN, Sherman SI, et al. Genetic alterations in the RAS/RAF/mitogen-activated protein kinase and phos- phatidylinositol 3 kihase/Akt signaling pathways in the follicular variant of papillary thyroid carcinoma [J]. Cancer, 2010, 116 (12) : 2974-2983.
  • 5Ricarte-Filho JC, Ryder M, Chitale DA, et al. Mutational pro- file of advanced primary and met a static radioactive iodine-re- fractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, andAKT1 [J]. Cancer Res, 2009, 69(11): 4885- 4893.
  • 6Garnett MJ, Marais R. Guilty as charged B-RAF is a human oncogene [J]. Cancer Cell, 2004, 6(4):313- 319.
  • 7Chiosea S, Nikiforova M, Zuo H, et al. A novel complex BRAF mutation detected in a solid variant of papillary thyroid carcino- ma[J]. EndocrPathol, 2009, 20(2):122-126.
  • 8Ciampi R, Knauf JA, Kerler R, et al. Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thy- roid cancer[J].J ClinInvest, 2005, 115(1) :94-101.
  • 9O'Neill CJ, Bullock M, Chou A, et al. BRAF(V600E) muta- tion is associated with an increased risk of nodal recurrence re- quiring reoperative surgery in patients with papillary thyroid cancer [J]. Surgery, 2010, 148(6):1139- 1145.
  • 10Trovisco V, Soares P, Preto A, et al. Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients~ age but not with turnout ag- gressiveness [J]. Virchows Arch, 2005, 446(6):589-595.

引证文献3

二级引证文献4

国际外科学杂志
2011年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部